Eiger BioPharmaceuticals, Inc.
EIGR
Rank in Stocks
#36463
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Share Price
$1.73
Last synced: 2025-06-17
Market Cap
$2.55M
Change (1 day)
-0.29%
Change (1 year)
-79.71%
Country
US
Trade Eiger BioPharmaceuticals, Inc. (EIGR)
Category
Healthcare
Market Capitalization of Eiger BioPharmaceuticals, Inc.(EIGR)
Market Cap: $2.55M
As of October 2026 Eiger BioPharmaceuticals, Inc. has a market cap of $2.55M. This makes Eiger BioPharmaceuticals, Inc. the world's 36463rd most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Eiger BioPharmaceuticals, Inc. from 2014 to 2026
EIGR compared with Top 5 Most Popular stocks
